System would use microbes for manufacturing small amounts of vaccines and other therapies.
For medics on the battlefield and doctors in remote or developing parts of the world, getting rapid access to the drugs needed to treat patients can be challenging.
Biopharmaceutical drugs, which are used in a wide range of therapies including vaccines and treatments for diabetes and cancer, are typically produced in large, centralized fermentation plants. This means they must be transported to the treatment site, which can be expensive, time-consuming, and challenging to execute in areas with poor supply chains.
Now a portable production system, designed to manufacture a range of biopharmaceuticals on demand, has been developed by researchers at MIT, with funding from the Defense Advanced Research Projects Agency (DARPA).
In a paper published today in the journal Nature Communications, the researchers demonstrate that the system can be used to produce a single dose of treatment from a compact device containing a small droplet of cells in a liquid.
In this way, the system could ultimately be carried onto the battlefield and used to produce treatments at the point of care. It could also be used to manufacture a vaccine to prevent a disease outbreak in a remote village, according to senior author Tim Lu, an associate professor of biological engineering and electrical engineering and computer science, and head of the Synthetic Biology Group at MIT’s Research Laboratory of Electronics.
“Imagine you were on Mars or in a remote desert, without access to a full formulary, you could program the yeast to produce drugs on demand locally,” Lu says.
The system is based on a programmable strain of yeast, Pichia pastoris, which can be induced to express one of two therapeutic proteins when exposed to a particular chemical trigger. The researchers chose P. pastoris because it can grow to very high densities on simple and inexpensive carbon sources, and is able to express large amounts of protein.
“We altered the yeast so it could be more easily genetically modified, and could include more than one therapeutic in its repertoire,” Lu says.
When the researchers exposed the modified yeast to estrogen ?-estradiol, the cells expressed recombinant human growth hormone (rHGH). In contrast, when they exposed the cells to methanol, the yeast expressed the protein interferon.
The cells are held within a millimeter-scale table-top microbioreactor, containing a microfluidic chip, which was originally developed by Rajeev Ram, a professor of electrical engineering at MIT, and his team, and then commercialized by Kevin Lee — an MIT graduate and co-author — through a spin-off company.
A liquid containing the desired chemical trigger is first fed into the reactor, to mix with the cells.
Inside the reactor, the cell-and-chemical mixture is surrounded on three sides by polycarbonate; on the fourth side is a flexible and gas-permeable silicone rubber membrane.
By pressurizing the gas above this membrane, the researchers are able to gently massage the liquid droplet to ensure its contents are fully mixed together.
“This makes sure that the one milliliter (of liquid) is homogenous, and that is important because diffusion at these small scales, where there is no turbulence, takes a surprisingly long time,” says Ram, who was also a senior author of the paper.
Because the membrane is gas permeable, it allows oxygen to flow through to the cells, while any carbon dioxide they produce can be easily extracted.
The device continuously monitors conditions within the microfluidic chip, including oxygen levels, temperature, and pH, to ensure the optimum environment for cell growth. It also monitors cell density.
If the yeast is required to produce a different protein, the liquid is simply flushed through a filter, leaving the cells behind. Fresh liquid containing a new chemical trigger can then be added, to stimulate production of the next protein.
Although other research teams have previously attempted to build microbioreactors, these have not have not had the ability to retain the protein-producing cells while flushing out the liquid they are mixed with, Ram says. “You want to keep the cells because they are your factory,” he says. “But you also want to rapidly change their chemical environment, in order to change the trigger for protein production.”
The researchers have demonstrated a very logical and practical way to produce biologic drugs, according to Luke P. Lee, a professor of bioengineering at the University of California at Berkeley, who was not involved in the research. Their smart biologics production technique uses one of the best integrated microfluidics systems, Lee says.
“It is a pragmatic solution for biomanufacturing, and the team’s flexible and portable platform shows an authentic way of producing personalized therapeutics,” he says.
The researchers are now investigating the use of the system in combinatorial treatments, in which multiple therapeutics, such as antibodies, are used together.
Combining multiple therapeutics in this way can be expensive if each requires its own production line, Lu says.
“But if you could engineer a single strain, or maybe even a consortia of strains that grow together, to manufacture combinations of biologics or antibodies, that could be a very powerful way of producing these drugs at a reasonable cost,” he says.
Learn more: Portable device produces biopharmaceuticals on demand
The Latest on: Biopharmaceuticals
[google_news title=”” keyword=”biopharmaceuticals” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Biopharmaceuticals
- Focused on the futureon April 25, 2024 at 8:04 am
U.S. Sen. Tom Carper reflected on the bold and promising new direction that is developing on the STAR Campus to provide access to medicines and biopharmaceuticals that can help people lead healthier ...
- Day One slips despite Ojemda approval as BofA says label “not a home run”on April 24, 2024 at 12:05 pm
Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) traded lower a day after the company received FDA approval for its lead candidate, Ojemda, while Bank of America expressed reservations about its ...
- Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fairon April 24, 2024 at 8:20 am
Day One Biopharmaceuticals won accelerated approval for pediatric brain cancer drug, Ojemda, with a potential market of around $1bn. Click for my DAWN update.
- Biopharmaceuticals Market Expansion: Anticipated To Reach USD 566 Billion By 2033, Reflecting A 8.2% Growth Rateon April 23, 2024 at 11:45 pm
According to Market.Us, the global biopharmaceuticals market is projected to expand from a valuation of USD 263 billion in 2022 to approximately USD 566 billion by 2032. This represents a compound ...
- Day One takes on Novartis with FDA nod for Ojemda in broader common childhood brain tumor useon April 23, 2024 at 7:13 pm
Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, the newcomer boasts an FDA approval covering a broader patient population. | Another drug ...
- Buy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemdaon April 23, 2024 at 3:05 pm
Day One Biopharmaceuticals (DAWN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
- Trading Update: Day One Biopharmaceuticals Inc (DAWN) Stock Endures 5.81% Monthly Volatilityon April 18, 2024 at 5:00 pm
The stock of Day One Biopharmaceuticals Inc (DAWN) has gone up by 12.02% for the week, with a 14.13% rise in the past month and a 14.21% rise in the past quarter. The volatility ratio for the week is ...
- Navidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextranon April 18, 2024 at 5:10 am
Discover Navidea Biopharmaceuticals Inc's innovative patent for conjugating metal chelating agents to dextran, free of crosslinking. Explore its potential in medical imaging and drug delivery.
- SK Biopharmaceuticals inks $58 million deal for pain treatment drugon April 18, 2024 at 1:32 am
SK Biopharmaceuticals signed a $58 million technology transfer deal with Ignis Therapeutics for nonnarcotic pain treatment candidate SKL22544.
- Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creationon April 16, 2024 at 6:20 am
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as PresidentKNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus ...
via Bing News